Literature DB >> 15084378

Immune activation status of CD8+ T cells infiltrating non-small cell lung cancer.

Andreas Trojan1, Mirjana Urosevic, Reinhard Dummer, Robin Giger, Walter Weder, Rolf A Stahel.   

Abstract

In a variety of human cancers, the presence of tumor-infiltrating T lymphocytes (TILs) is associated with tumor regression and favorable prognosis. Local interferon (IFN)-gamma secretion from activated T cells is supposed to induce a specific immune response leading to tumor-specific cytotoxicity. Nonetheless, significance and properties of TILs still remains controversial in lung cancer patients. We determined CD8+ T cell counts in 31 patients with non-small cell lung cancer (NSCLC) by immunohistochemistry, and assessed T-cell immune activation status in a subset of patients by measuring IFN-gamma mRNA expression by quantitative PCR (TaqMan). Semi-quantitative immunohistochemical analysis revealed significantly higher CD8+ T cell counts within the tumor as when compared to the invasive margin. CD8+ T cells immune activation status, represented in the IFN-gamma/CD8 mRNA ratio, correlated with the median number of CD8+ T cells presented at the tumor-host interface. Neither tumor histology and grade, nor CD8+ T cell counts and IFN-gamma/CD8 ratio could demonstrate an influence on overall survival in these patients. Our results indicate that CD8+ T cells infiltrating the tumor cell nests may be inadequately activated and thus incapable of mounting an effective anti-tumor immune response.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15084378     DOI: 10.1016/j.lungcan.2003.11.004

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  14 in total

1.  Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma: Tumor-Infiltrating CD10+ Neutrophil/CD20+ Lymphocyte Ratio as an Independent Prognostic Factor.

Authors:  Kyuichi Kadota; Jun-Ichi Nitadori; Hideki Ujiie; Daniel H Buitrago; Kaitlin M Woo; Camelia S Sima; William D Travis; David R Jones; Prasad S Adusumilli
Journal:  J Thorac Oncol       Date:  2015-09       Impact factor: 15.609

2.  Screening a novel six critical gene-based system of diagnostic and prognostic biomarkers in prostate adenocarcinoma patients with different clinical variables.

Authors:  Hadia Munir; Fawad Ahmad; Sajid Ullah; Saeedah Musaed Almutairi; Samra Asghar; Tehmina Siddique; Mostafa A Abdel-Maksoud; Rabab Ahmed Rasheed; Fatma Alzahraa A Elkhamisy; Mohammed Aufy; Hamid Yaz
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

3.  Innate immune therapy with a Bacillus Calmette-Guérin cell wall skeleton after radical surgery for non-small cell lung cancer: a case-control study.

Authors:  Ken Kodama; Masahiko Higashiyama; Koji Takami; Kazuyuki Oda; Jiro Okami; Jun Maeda; Takashi Akazawa; Misako Matsumoto; Tsukasa Seya; Mariko Wada; Kumao Toyoshima
Journal:  Surg Today       Date:  2009-03-12       Impact factor: 2.549

4.  Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence.

Authors:  Kei Suzuki; Kyuichi Kadota; Camelia S Sima; Jun-ichi Nitadori; Valerie W Rusch; William D Travis; Michel Sadelain; Prasad S Adusumilli
Journal:  J Clin Oncol       Date:  2012-12-26       Impact factor: 44.544

5.  Prognostic significance of tumor-infiltrating CD8⁺ or CD3⁺ T lymphocytes and interleukin-2 expression in radically resected non-small cell lung cancer.

Authors:  Chuntao Tian; Shixin Lu; Qingxia Fan; Weijie Zhang; Shunchang Jiao; Xiao Zhao; Zhiyong Wu; Liang Sun; Liuxing Wang
Journal:  Chin Med J (Engl)       Date:  2015-01-05       Impact factor: 2.628

Review 6.  Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer.

Authors:  Angel Qin; David G Coffey; Edus H Warren; Nithya Ramnath
Journal:  Cancer Med       Date:  2016-07-15       Impact factor: 4.452

7.  The distribution and function of human memory T cell subsets in lung cancer.

Authors:  Si Yuan Sheng; Yong Gu; Chuan Gang Lu; Jian Yong Zou; Hai Hong; RongFu Wang
Journal:  Immunol Res       Date:  2017-06       Impact factor: 2.829

Review 8.  Tumor-induced CD8+ T-cell dysfunction in lung cancer patients.

Authors:  Heriberto Prado-Garcia; Susana Romero-Garcia; Dolores Aguilar-Cazares; Manuel Meneses-Flores; Jose Sullivan Lopez-Gonzalez
Journal:  Clin Dev Immunol       Date:  2012-10-17

Review 9.  Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment.

Authors:  Marlies E Heuvers; Joachim G Aerts; Robin Cornelissen; Harry Groen; Henk C Hoogsteden; Joost P Hegmans
Journal:  BMC Cancer       Date:  2012-12-05       Impact factor: 4.430

10.  Smoker and non-smoker lung adenocarcinoma is characterized by distinct tumor immune microenvironments.

Authors:  Xufan Li; Jia Li; Pin Wu; Liyuan Zhou; Bingjian Lu; Kejing Ying; Enguo Chen; Yan Lu; Pengyuan Liu
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.